Supreme Court Refuses Merck’s Appeal Over $200 Million Gilead Verdict

Drug Industry Daily
A A
The Supreme Court declined to consider Merck’s appeal of a California court ruling that overturned a $200 million jury award against Gilead over a hepatitis C drug patent.

To View This Article:

Login

Subscribe To Drug Industry Daily